Home › GE Healthcare Invests In FISH Technologies For Leukemia And Lymphoma Testing
 

Keywords :   


GE Healthcare Invests In FISH Technologies For Leukemia And Lymphoma Testing

2014-03-05 04:40:25| drugdiscoveryonline Home Page

GE Healthcare recently announced that Clarient Diagnostic Service, Inc., a GE Healthcare company, has made significant upgrades to its fluorescence in situ hybridisation (FISH) technologies to improve virtual analysis of testing results for a variety of blood diseases, including leukemia, lymphoma, myelodysplastic syndrome and myeloma

Tags: technologies testing fish healthcare

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
11.05Weekly Recap: Hempel, Sherwin-Williams Top This Weeks Stories
11.05LG CHI Color Master Factory Is Awarded Patent
11.05AgriWebb raises $7.2m to fuel further innovation in sustainable beef production
11.05YouGov Unveils Americans Skincare Routines
11.05Naples Soap Company Reports Revenue Surge Amidst Tourist Season
11.05Indian Perfume Brand Eze Perfumes Enters US Market
11.05LOccitane Travel Retail Showcases Travel Retail Brand Portfolio at TFWA Asia Pacific
10.05How crops are being disaster-proofed
More »